Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MabCure Inc. (MBCI)
White Plains, NY, US
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -50.00% | +100.00% | +100.00% | +100.00% | +100.00% | +0.00% | -95.92% | -96.67% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%-765.8% Q4'11: -1,664.7% (vs Q4'10)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-2,406.7% Q4'11: +29.1% (vs Q4'10)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-2,415.6% Q4'11: -2,234.0% (vs Q4'10)
-
ROIC Medical - Pharmaceuticals: +6.1%-302.7% Q4'11: -1,119.6% (vs Q4'10)
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.7% Q4'11: +2.5% (vs Q4'10)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.02× Q4'11: -0.01× (vs Q4'10)
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jehu Hand | 865.0K | 74.80% | 150.0K | 715.0K | 150.0K | 10.00 | IN | United States of America | 2015-11-10 | ↗ |
| 2 | Jackson Clearing Corporation | 715.0K | 61.80% | 715.0K | — | 715.0K | 10.00 | CO | US Virgin Islands | 2015-11-10 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011-09-24 | Berdugo Gad | Director | — | D | Stock Option (Right to Buy) | 120,000 | 0.45 | 54.0K | 0 | — | ↗ |
| 2011-05-19 | Berdugo Gad | Director | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.50 | 100.0K | 320,000 | — | ↗ |
| 2008-07-07 | KATZ STEVEN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jehu Thomas Degerold Hand | Chief Executive & Financial Officer and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MBCI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
